Next Article in Journal
Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel
Previous Article in Journal
Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 11
Issue 12
10.3390/pharmaceutics11120689
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceutics 2019, 11(9), 478.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles. Pharmaceutics, 2019, 11(9), 478

by
Takanori Kanazawa
1,2,*,†,
Takumi Kurano
1,2,†,
Hisako Ibaraki
1,
Yuuki Takashima
1,
Toyofumi Suzuki
2 and
Yasuo Seta
1
1
School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
2
School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceutics 2019, 11(12), 689; https://doi.org/10.3390/pharmaceutics11120689
Submission received: 9 December 2019 / Accepted: 9 December 2019 / Published: 17 December 2019
Browse Figures
Versions Notes
The appropriate information for the reprint used with permission from [2] is missing in our paper (Figure 2B) [1]. Therefore, the appropriate credit is inserted in the caption of Figure 2B as below. This insertion does not affect the scientific results. The manuscript will be updated, and the original article will remain online webpage (https://www.mdpi.com/1999-4923/11/9/478) with a reference to this correction.

References

  1. Kanazawa, T.; Kurano, T.; Ibaraki, H.; Takashima, Y.; Suzuki, T.; Seta, Y. Therapeutic effects in a transient middle cerebral artery occlusion rat model by nose-to-brain delivery of anti-TNF-alpha siRNA with cell-penetrating peptide-modified polymer micelles. Pharmaceutics 2019, 11, 478. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Kanazawa, T.; Morisaki, K.; Suzuki, S.; Takashima, Y. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles. Mol. Pharm. 2014, 11, 1471–1478. [Google Scholar] [CrossRef] [PubMed]
Pharmaceutics 11 00689 g002a 550Pharmaceutics 11 00689 g002b 550
Figure 2. Cellular uptake of siRNA and cytotoxicity by PEG-PCL-Tat micelles in rat RN33B neuronal cells. RN33B cells were transfected with naked FAM-siRNA (1 μg), FAM-siRNA (1 μg) complexed with PEG-PCL-Tat (N/P ratio: 5–30), or Lipotrust as positive control. (A) After incubation for 4 h, the cellular uptake (%) of FAM-siRNA into RN33B cells was determined by flow cytometry. (B) Adapted with permission from [2]. Copyright 2019 American Chemical Society. After incubation for 3 h, in vitro cytotoxicity by PEG-PCL-Tat was determined by WST-8 assay. Each bar represents the mean ± S.D. (n = 4). **p < 0.01 vs. other groups, n.s.p > 0.05.
Figure 2. Cellular uptake of siRNA and cytotoxicity by PEG-PCL-Tat micelles in rat RN33B neuronal cells. RN33B cells were transfected with naked FAM-siRNA (1 μg), FAM-siRNA (1 μg) complexed with PEG-PCL-Tat (N/P ratio: 5–30), or Lipotrust as positive control. (A) After incubation for 4 h, the cellular uptake (%) of FAM-siRNA into RN33B cells was determined by flow cytometry. (B) Adapted with permission from [2]. Copyright 2019 American Chemical Society. After incubation for 3 h, in vitro cytotoxicity by PEG-PCL-Tat was determined by WST-8 assay. Each bar represents the mean ± S.D. (n = 4). **p < 0.01 vs. other groups, n.s.p > 0.05.
Pharmaceutics 11 00689 g002aPharmaceutics 11 00689 g002b

Share and Cite

MDPI and ACS Style

Kanazawa, T.; Kurano, T.; Ibaraki, H.; Takashima, Y.; Suzuki, T.; Seta, Y. Correction: Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles. Pharmaceutics, 2019, 11(9), 478. Pharmaceutics 2019, 11, 689. https://doi.org/10.3390/pharmaceutics11120689

AMA Style

Kanazawa T, Kurano T, Ibaraki H, Takashima Y, Suzuki T, Seta Y. Correction: Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles. Pharmaceutics, 2019, 11(9), 478. Pharmaceutics. 2019; 11(12):689. https://doi.org/10.3390/pharmaceutics11120689

Chicago/Turabian Style

Kanazawa, Takanori, Takumi Kurano, Hisako Ibaraki, Yuuki Takashima, Toyofumi Suzuki, and Yasuo Seta. 2019. "Correction: Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles. Pharmaceutics, 2019, 11(9), 478" Pharmaceutics 11, no. 12: 689. https://doi.org/10.3390/pharmaceutics11120689

APA Style

Kanazawa, T., Kurano, T., Ibaraki, H., Takashima, Y., Suzuki, T., & Seta, Y. (2019). Correction: Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles. Pharmaceutics, 2019, 11(9), 478. Pharmaceutics, 11(12), 689. https://doi.org/10.3390/pharmaceutics11120689

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop